Media OutReach
Bora Group to Acquire MacroGenics’ GMP Manufacturing Operations for $122.5M
Securing Maryland-Based Drug-Substance Facility and Existing Commercial Orders to Scale the Group’s Integrated Technology Platform
HONG KONG SAR – Media OutReach Newswire – 12 May 2026 – Bora Pharmaceuticals (“Bora” or “Bora Group”; TWSE: 6472; OTCQX: BORAY) today announced that its Board of Directors has approved the acquisition of the GMP manufacturing operations, including the CDMO business, of MacroGenics, Inc. (NASDAQ: MGNX), for total consideration of US$122.5 million, subject to customary working capital adjustments, and a contingent consideration of up to $5 million based on future customer orders. The transaction includes a biologics drug substance manufacturing facility located in Rockville, Maryland and an associated warehousing center in Frederick, Maryland. Upon closing of the acquisition, the Company will sign a long-term CDMO Service Agreement with MacroGenics.
Following closing, Bora Group intends to leverage the Rockville Site in cooperation with Tanvex Biopharma (TWSE: 6541), which operates the Group’s biologics CDMO franchise under the “Bora Biologics” brand. Together with Bora’s sterile drug product capabilities, this is expected to scale the Group’s end-to-end biologics platform.
The Rockville facility has operated as an outsource manufacturing partner since 2022 and is equipped with five 2,000-liter and two 500-liter single-use bioreactors and fully integrated QC and analytical laboratories and has been inspected by both the U.S. FDA and Japan’s PMDA. From the transaction, Bora is expected to assume a substantial backlog for the size of its Bora Biologics CDMO business, including commercial-stage monoclonal antibody programs, clinical-stage programs, and a strong project pipeline. Commercial manufacturing currently accounts for more than half of the site’s revenue.
“This acquisition marks a pivotal step in strengthening Bora’s integrated biologics CDMO platform in the United States”, said Bobby Sheng, Chairman and CEO of Bora Group. “With the addition of the Rockville site, Bora Biologics total drug substance capacity would be 20,000-liter (SUB) and Bora Group will integrate our in-house DS (Drug Substance) and DP (Drug Product) capabilities and network investments over the next 12 to 18 months to offer global biotech customers a seamless offering allowing customers to advance programs from development through commercial supply with one single partner.”
Bora’s Board of Directors has authorized the Chairman to finalize the transaction in line with market conditions and the regulatory environment. For the year ended December 31, 2025, MacroGenics reported contract manufacturing revenue of $52.6 million.
Hashtag: #BoraPharmaceuticals
The issuer is solely responsible for the content of this announcement.
About Bora:
Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.
By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.
For more, please visit:
https://www.bora-corp.com
https://www.boracdmo.com
Disclaimer:
This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.
Through DaaS, enterprise customers can access drone equipment, trained personnel, mission execution, data collection and project deliverables without purchasing and maintaining a complete in-house drone system. The model extends ZenaTech’s business beyond equipment sales and enables the company to generate recurring service revenue from customers’ operational requirements.
ZenaTech reported revenue of CAD 8.4 million for the first quarter of 2026, an increase of 640% from CAD 1.13 million in the same period of 2025. DaaS contributed approximately CAD 7.8 million, accounting for around 93% of quarterly revenue.
In 2025, the company generated annual revenue of CAD 12.9 million, up 558% from approximately CAD 2 million in 2024. DaaS contributed approximately CAD 10.1 million during its first full year of operations, representing around 78% of total annual revenue.
Acquisitions Support Service Network Expansion
ZenaTech has expanded its DaaS operations through a combination of internal technology development and acquisitions. The acquired businesses bring existing customers, professional teams and local operating capabilities, while ZenaTech gradually introduces drones, automated data collection and AI-supported analytics into selected workflows.
In 2025, the company completed 20 acquisitions, including 19 businesses providing engineering data, facility inspection and related professional services, as well as one enterprise software company.
By June 2026, ZenaTech had completed its 24th DaaS-related acquisition and expanded its services into property cleaning, facility inspection and maintenance.
Through its ZenaDrone subsidiary, ZenaTech has also developed drone products for indoor and outdoor operations. The IQ Quad supports site data collection, engineering imagery and 3D modelling, while the IQ Nano uses barcode and RFID scanning to support inventory records, shelf inspections and indoor data collection.
The company’s reported revenue growth, acquisition activity and DaaS contribution provide investors following the AI and drone sectors with measurable indicators of how its technologies are being integrated into commercial operations and converted into service revenue.
Hashtag: #ZenaTech
The issuer is solely responsible for the content of this announcement.
About ZenaTech
ZenaTech (Nasdaq: ZENA) is a technology company specialising in AI-powered drones, Drone-as-a-Service (DaaS), enterprise SaaS solutions and related technologies. Through its ZenaDrone subsidiary, the company develops drone products and software for commercial applications including engineering data collection, agriculture, warehouse management, facility inspection and property maintenance. ZenaTech combines its technology capabilities with a growing professional service network to support the adoption of drone-based solutions across a range of operational environments.
Media OutReach
A Defining Milestone for Gene Solutions: SPOT-MAS Multi-Cancer Screening Test Receives U.S. FDA Breakthrough Device Designation
The proposed indications for use describe SPOT-MAS 10 as a qualitative in vitro diagnostic test performed on plasma derived from a single direct-draw venous whole blood specimen. The test analyzes circulating cell-free DNA methylation and fragmentomic signatures using a machine-learning-based algorithm to detect a cancer-associated signal. It is intended for use as an adjunctive screening test in asymptomatic adults aged 40 years and older to assist in detecting cancers within the scope of the assay. These include five common cancers — breast, lung, liver, colorectal and gastric cancers — and five aggressive, less common cancers that currently lack standard screening methods — ovarian, pancreatic, esophageal, endometrial and head & neck cancers.
SPOT-MAS has been developed through years of rigorous scientific research and clinical development. In March 2025, SPOT-MAS became the first multi-cancer screening blood test in Asia to complete a large prospective cohort validation, with the K-DETEK study evaluating more than 9,000 asymptomatic participants and demonstrating strong performance, including high specificity and the ability to identify cancer-associated signals across multiple cancer types.
Since then, SPOT-MAS has been used in more than 100,000 individuals in real-world practice, with consistent performance observed beyond controlled study settings. Real-world data were presented at ESMO Asia 2025 and were featured at ASCO Breakthrough 2026 in Singapore.
The platform is built on a multi-omic approach— integrating genetics, epigenetics, and fragmentomics — together with AI-driven analysis, large-scale prospective validation, growing real-world evidence and focus on cancer types with high clinical relevance in the regions where the test is deployed.
For the United States, Breakthrough Device Designation provides Gene Solutions with a prioritized channel of engagement with the FDA as the company advances its U.S. development and validation plans.
Looking ahead, Gene Solutions will continue to collaborate with academic, clinical, laboratory, commercial and strategic partners to support responsible adoption of SPOT-MAS in accordance with local regulations, clinical guidelines and best practices.
Important Regulatory Notice: SPOT-MAS 10 has received U.S. FDA Breakthrough Device Designation. Breakthrough Device Designation is not FDA approval, clearance or marketing authorization. The device remains subject to applicable FDA regulatory review requirements, and the designation does not guarantee future FDA approval, clearance or authorization.
For more information, visit https://spotmas.com.hk
Contact:
hk***@***********ns.com
Source: Gene Solutions Hong Kong Limited.
SPOTMAS_062026_04
Hashtag: #SPOTMAS
https://spotmas.com.hk/The issuer is solely responsible for the content of this announcement.
Media OutReach
St Francis Methodist School International Shares 2023–2024 WACE Outcomes and Student Journeys
Overview of the WACE Curriculum at SFMS
SFMS International is among a small number of institutions in Singapore offering the WACE curriculum and has delivered this programme for over 23 years. The WACE is a recognised senior secondary qualification awarded by the School Curriculum and Standards Authority (SCSA) on behalf of the Ministry of Education, Western Australia. It prepares students for university admission both locally and internationally.
SFMS is also currently the only school in Singapore offering a Senior High Preparatory Pathway (WACE) for students in Years 9–10. This introduces students to the structure and expectations of the curriculum earlier, building familiarity with subject content and assessment formats before progressing to the senior years. Additionally, subject selection in Years 11A and 12A is structured to meet university entry requirements and reflect students’ academic interests.
Academic Outcomes and University Placements
In 2023, 8 out of 12 WACE graduates from SFMS International achieved ATAR scores above 90, meeting the eligibility criteria for universities such as the National University of Singapore (NUS) and Nanyang Technological University (NTU). The cohort’s top scorer, Wang Dawei, recorded an ATAR of 96.15 and enrolled at NTU to study Business and International Trading. In addition to local placements, graduates were admitted to international universities such as the University of Melbourne and Fudan University in China.
In 2024, 2 out of 8 graduates also attained ATAR scores above 90. The highest scorer, Youn Chae-Won, achieved an ATAR of 95.3. Her university placement is currently pending.
Student Journeys and Holistic Development
Students in the WACE programme at SFMS International engage in both academic and co-curricular activities as part of their overall learning experience. Recent graduates have taken part in service learning, subject specialisation, and personal reflection throughout their time in the pre-university programme.
Youn Chae-Won, the 2024 valedictorian, joined SFMS International from Korea in 2021. Over time, she adjusted to a new academic environment and explored subjects such as accounting, which influenced her interest in finance-related pathways. She also took part in various aspects of school life, including a service learning trip to Bintan in 2023, where students supported local sanitation efforts. Her involvement in both academic and co-curricular settings marked a broad engagement with school life during her time at SFMS.
Andrew Zhuang, who enrolled in SFMS International in 2019, pursued subjects such as Business Management, Accounting, and English as an Additional Language (EALD). Beyond academics, he was involved in community fundraising and joined the same Bintan service trip. He also attended weekly chapel sessions and received support from peers and teachers during a period of health-related absence.
These outcomes reflect the ongoing role of the WACE programme at SFMS International in supporting students through both academic pathways and broader educational experiences. Under the leadership of Principal Mr Lee Hak Boon, the school continues to emphasise academic planning, subject selection, and student wellbeing as part of its overall approach to pre-university education.
Hashtag: #StFrancisMethodistSchoolInternational
https://www.sfms.edu.sg/
https://www.facebook.com/sfms.singapore
https://www.instagram.com/sfms_sg/
https://www.youtube.com/channel/UC_bb9hcNhAk7WgYBE_FI61A/featured
The issuer is solely responsible for the content of this announcement.
About St Francis Methodist School International
Established in 1960, St Francis Methodist School International (SFMS) is an educational institution in Singapore that offers primary, secondary, and pre-university programmes. The school provides several academic pathways, including the International Baccalaureate (IB), Cambridge IGCSE, and the Western Australian Certificate of Education (WACE), preparing students for further studies in local and overseas institutions.
